1 Gustave L Levy Pl# 1272New York, NY 10029
Fax+1 212-987-4675
Overview of Dr. Mehrazin
Dr. Mehrazin’s clinical expertise is in robotic surgery, laparoscopic, and open surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
Education & Training
Temple University HospitalFellowship, Minimally Invasive Urologic Surgery, 2012 - 2014
University of TennesseeResidency, Urology, 2008 - 2012- University of TennesseeInternship, Transitional Year, 2007 - 2008
Medical University of the AmericasClass of 2006
Certifications & Licensure
NY State Medical License 2014 - 2027
PA State Medical License 2011 - 2014
American Board of Urology Urology
Society of Urologic OncologySociety of Urologic Oncology
Clinical Trials
- Use of Perioperative Pain Blocks In Urological Surgery Start of enrollment: 2019 Nov 11
Publications & Presentations
PubMed
- Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer.Reuben Ben-David, Ahmed Eraky, Brenda Hug, Matthew D Galsky, Che-Kai Tsao
BJU International. 2025-12-01 - 2 citationsImpact of Systemic Therapy for Renal Cell Carcinoma With a Tumor Thrombus: Results From the Intercontinental Collaboration on Renal Cell Carcinoma Database.Maxwell Sandberg, Gregory Russell, Dana Feldman, Mitchell Hayes, Reuben Ben David
Clinical Genitourinary Cancer. 2025-12-01 - Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine/docetaxel.Ahmed Eraky, Reuben Ben-David, Brenda Hug, Kaushik P Kolanukuduru, Neeraja Tillu
BJU International. 2025-12-01
Journal Articles
- Lymphopenia as an independent predictor of worse survival in papillary renal cell carcinoma.Reza Mehrazin, Robert G. Uzzo, Alexander Kutikov, Jeffrey J. Tomaszewski, Serge Ginzburg, Karen J. Ruth, Essel Al-Saleem, David Y. T. Chen, Rosalia Viterbo, Richard E...., J Clin Oncol 32, 2014 (suppl 4; abstr 397)
Press Mentions
Novel Chemotherapy Delivery System May Fill Key Gap in Bladder Cancer TreatmentMay 3rd, 2023- Minimally Invasive Partial Nephrectomy Does Not Worsen Cancer OutcomesFebruary 25th, 2022
Kidney Cancer Gets Too Little AttentionOctober 11th, 2015- Join now to see all
Professional Memberships
- Member
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
